In particular, overexpression of HER2/neu (also known as ERBB2) has been found to correlate with increased tumor aggression, metastatic potential, and poor prognosis for disease-free survival in patients with breast, colorectal, ovarian, lung, prostate and salivary gland tumors.[6], [7] The ERBB signaling network and the role of HER2/neu in cancer biology has been the subject of several excellent reviews.[7]–[11]. The gene discussed is EGFR; the disease is cancer.